{"id":209233,"date":"2025-09-08T03:40:14","date_gmt":"2025-09-08T03:40:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/209233\/"},"modified":"2025-09-08T03:40:14","modified_gmt":"2025-09-08T03:40:14","slug":"a-100-effective-cancer-vaccine-russias-enteromix-achieves-success-in-trials-heres-the-full-report-you-need-to-read","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/209233\/","title":{"rendered":"A 100% effective cancer vaccine? Russia\u2019s Enteromix achieves success in trials; Here\u2019s the full report you need to read"},"content":{"rendered":"

A vaccine that could change the way we fight cancer is making headlines. Russia\u2019s Enteromix has reportedly achieved 100% efficacy in preclinical trials, showing both safety and strong tumour-fighting abilities, according to a report by Tass.<\/p>\n

Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), revealed the results at the Eastern Economic Forum (EEF). <\/p>\n

\u201cThe research spanned several years, with the last three dedicated to mandatory preclinical studies. The vaccine is now ready for use; we are awaiting official approval,\u201d Tass quoted her as saying.
Skvortsova stressed that repeated administration of the vaccine remained safe, while also showing impressive results. Tumour growth slowed by 60\u201380%, survival rates improved, and significant reductions in tumour size were observed.First target: colorectal cancer
The vaccine\u2019s initial focus will be on colorectal cancer, a leading cause of cancer-related deaths worldwide. But the research does not stop there. Scientists are also developing versions for glioblastoma, a highly aggressive brain tumour, and specific types of melanoma, including ocular melanoma, all of which are at advanced stages of study.
\"ETLive Events
Most of us associate vaccines with childhood diseases such as measles or chickenpox. These train the immune system to recognise dangerous germs. Cancer vaccines work on a similar principle, but instead of viruses, they help the body spot and attack cancer cells.According to the American Cancer Society, some cancer vaccines already exist for bladder and prostate cancers, while the HPV vaccine prevents several types of cancer before they begin. Enteromix, however, belongs to a growing line of therapeutic vaccines designed to treat cancer directly, making the body\u2019s natural defences more powerful.Global stage for a breakthrough
The announcement came during the 10th Eastern Economic Forum in Vladivostok (3\u20136 September), where over 8,400 delegates from 75 countries gathered under the theme \u201cThe Far East: Cooperation for Peace and Prosperity.\u201d More than 100 thematic sessions were held, but it was Enteromix that stole the spotlight.<\/p>\n

If approved, this Russian vaccine could be a milestone in the fight against one of the world\u2019s deadliest diseases, potentially reshaping cancer treatment as we know it.<\/p>\n

Inputs from ANI<\/p>\n

Add \"ET as a Reliable and Trusted News Source<\/p>\n","protected":false},"excerpt":{"rendered":"A vaccine that could change the way we fight cancer is making headlines. Russia\u2019s Enteromix has reportedly achieved…\n","protected":false},"author":3,"featured_media":209234,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[114881,82338,114885,114791,114882,114880,114883,210,114884,114887,114886,67,132,68],"class_list":{"0":"post-209233","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-100-cancer-vaccine-efficacy","9":"tag-cancer-immunotherapy","10":"tag-cancer-treatment-breakthrough","11":"tag-cancer-vaccine","12":"tag-colorectal-cancer-treatment","13":"tag-enteromix-russia","14":"tag-glioblastoma-vaccine","15":"tag-health","16":"tag-melanoma-vaccine","17":"tag-russia-cancer-research","18":"tag-tass-cancer-vaccine-report","19":"tag-united-states","20":"tag-unitedstates","21":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115166604531060310","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/209233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=209233"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/209233\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/209234"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=209233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=209233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=209233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}